U.S. President Donald Trump stated “any and all” goods from countries found to be supplying Iran with weapons would be subject to sanctions. This also touches on aspects of earnings report.

It comes after the U.S. and Iran agreed a two-week ceasefire.

Affected countries would be subject to the levy “immediately,” with no “exclusions or exemptions,” he added in a Truth Social post on Wednesday.

The U.S. will impose tariffs of 50% on “any and all” goods imported to the country from any nation “supplying military weapons to Iran,” President Donald Trump commented Wednesday.

Trump noted in a Truth Social post that any country found to be supplying Iran with weapons would be subject to the levy “immediately,” with no “exclusions or exemptions.”

The president wrote: “A Country supplying Military Weapons to Iran will be immediately tariffed, on any and all goods sold to the United States of America, 50%, effective immediately. There will be no exclusions or exemptions!” Furthermore, experts in portfolio note the continued relevance.

It came as Trump mentioned the U.S. would “work closely” with Iranian authorities, following the ceasefire agreement proclaimed on Tuesday and what Trump called “very productive regime change.”

Trump noted in a separate Truth Social post that “there will be no enrichment of uranium” and that many of the 15 points in the U.S. peace proposals have already been agreed.

The U.S. and Iran will discuss tariffs and sanctions relief, Trump added.

The vast bulk of Trump’s “reciprocal” tariffs, imposed last year, were struck down by the Supreme Court in February.

the White House has effectively rebuilt its tariff regime with its application of mechanisms within existing trade laws , on the other hand – such as Section 301 probes.

Metals are a key feature of the existing tariff regime, which currently imposes a 50% levy on products made entirely or almost entirely of steel, aluminum, or copper. There is a 25% tariff on derivative products “substantially made” of these metals.

From late July 2026, larger firms will face a 100% tariff on patented pharmaceutical products and ingredients. Smaller pharma companies will face the novel tariff rate from late September.